Drug Trial Radar · NCT03322462
Tau Screening Study in Patients With Early Symptomatic AD
Last checked: Nov 20, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Nov 21, 2017
Primary completion
Aug 31, 2018
Study completion Aug 31, 2018
Sponsor
- Lead sponsor
- Avid RadiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Conditions
- Alzheimer Disease
Interventions
Flortaucipir F18Drug
370 megabecquerel (MBq) IV single-dose
Brain PET ScanProcedure
positron emission tomography (PET) scan of the brain
Primary outcomes
What the sponsor says the trial is designed to measure.
- Flortaucipir Qualitative Results (Visual Reads)Time frame: baseline scan
- Flortaucipir Quantitative Results (SUVr)Time frame: baseline scan
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Pacific Research Network
San Diego, California
Syrentis Clinical Research
Santa Ana, California
Brain Matters Research
Delray Beach, Florida
Bioclinica (Compass Research)
Orlando, Florida
Axiom Clinical Research
Tampa, Florida
Boston Center for Memory
Newton, Massachusetts
PMG Research
Winston-Salem, North Carolina
Abington Neurological Associates
Willow Grove, Pennsylvania
The Memory Clinic
Bennington, Vermont
Toronto Memory Program
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.